Myocardial Infarction — The Adherence and Knowledge Exchange Heart and Stroke Medicines Study
Citation(s)
Ahmad M, Schwalm JD, Velianou JL, Natarajan MK Impact of routine in-hospital assessment of low-density lipoprotein levels and standardized orders on statin therapy in patients undergoing percutaneous coronary interventions. J Invasive Cardiol. 2005 Oct;17(10):518-20.
Hudson M, Richard H, Pilote L Parabolas of medication use and discontinuation after myocardial infarction--are we closing the treatment gap? Pharmacoepidemiol Drug Saf. 2007 Jul;16(7):773-85.
Rasmussen JN, Chong A, Alter DA Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007 Jan 10;297(2):177-86.
Tu JV, Donovan LR, Lee DS, Wang JT, Austin PC, Alter DA, Ko DT Effectiveness of public report cards for improving the quality of cardiac care: the EFFECT study: a randomized trial. JAMA. 2009 Dec 2;302(21):2330-7. doi: 10.1001/jama.2009.1731. Epub 2009 Nov 18.
Yusuf S, Reddy S, Ounpuu S, Anand S Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2001 Nov 27;104(22):2746-53. Review.
TAKEmeds Program: The Adherence and Knowledge Exchange Heart and Stroke Medicines Study
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
